Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study
Abstract
Increased area of the substantia nigra (SN) associated to iron deposition has been proposed as a specific marker for Parkinson's disease (PD). Echogenicity, assessed by transcranial sonography (TCS), has been used to measure such an iron deposition. On the other hand, ferroxidase activity is known to play a role in brain iron metabolism and thus could be involved in increased SN echogenicity of PD patients. The present study was conducted to search for a possible correlation between both markers: TCS of SN and plasma ferroxidase activity. Twenty-one PD patients and 13 healthy volunteers (HV) were included. Mean SN sonographic areas were 0.31 cm² for PD patients and 0.12 cm² for HV (P < 0.001), while plasma ferroxidase activity was reduced in PD patients (P < 0.001). Interestingly, plasma ferroxidase activity was inversely correlated with the SN size by TCS (R² = 0.31), suggesting a relationship between the two markers.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A contributing factor to the increased iron accumulation in Parkinson's disease might be increased DMT1 activity or decreased ferroxidase activity of ceruloplasmin, both of which would increase total intracellular iron.
“A contributing factor to the increased iron accumulation in Parkinson’s disease might be increased DMT1 activity or decreased ferroxidase activity of ceruloplasmin, both of which would increase total intracellular iron, as reported in an animal model of Parkinson’s disease109 and in patients.131–134”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [133]
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · see citing works
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053 · see citing works
Progressive Supranuclear Palsy
Steele, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,930 · see citing works
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801 · see citing works
Brain iron pathways and their relevance to Parkinson's disease
Berg, D., Gerlach, M., Youdim, M. B. H., Double, K. L., Zecca, L., Riederer, P., & Becker, G. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00608.x · Cited by 362 · see citing works
Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings
Berg, D., Siefker, C., & Becker, G. (2001) · Journal of Neurology · doi:10.1007/s004150170114 · Cited by 305 · see citing works
The transition metals copper and iron in neurodegenerative diseases
Rivera-Mancía, S., Pérez‐Neri, I., Rı́os, C., Tristán-López, L. A., Rivera-Espinosa, L., & Montes, S. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.04.010 · Cited by 243 · see citing works
Self-citationBrain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes
Walter, U., Niehaus, L., Probst, T., Benecke, R., Meyer, B.-U., & Dressler, D. W. (2003) · Neurology · doi:10.1212/wnl.60.1.74 · Cited by 229 · see citing works
Zecca, L., Berg, D., Arzberger, T., Ruprecht, P., Rausch, W. D., Musicco, M., Tampellini, D., Riederer, P., Gerlach, M., & Becker, G. (2005) · Movement Disorders · doi:10.1002/mds.20550 · Cited by 214 · see citing works
Role of Ceruloplasmin in Cellular Iron Uptake
Mukhopadhyay, C. K., Attieh, Z. K., & Fox, P. L. (1998) · Science · doi:10.1126/science.279.5351.714 · Cited by 199 · see citing works
Walter, U., Wittstock, M., Benecke, R., & Dressler, D. W. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200015 · Cited by 149 · see citing works
Epidemiology of Parkinsonʼs disease and akinetic syndromes
Tanner, C. M., & Aston, D. A. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200008000-00010 · Cited by 133 · see citing works
Jin, L., Wang, J., Zhao, L., Jin, H., Fei, G., Zhang, Y., Zeng, M., & Zhong, C. (2010) · Brain · doi:10.1093/brain/awq319 · Cited by 129 · see citing works
Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy
Walter, U., Dressler, D. W., Wolters, A., Probst, T., Großmann, A., & Benecke, R. (2004) · Neurology · doi:10.1212/01.wnl.0000133006.17909.32 · Cited by 119 · see citing works
Copper, Ceruloplasmin, Superoxide Dismutase and Iron Parameters in Parkinson's Disease
Tórsdóttir, G., Kristinsson, J., Sveinbjörnsdóttir, S., Snædal, J., & Jøhannesson, T. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb02015.x · Cited by 115 · see citing works
Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease
Walter, U., Dressler, D. W., Wolters, A., Wittstock, M., & Benecke, R. (2006) · Movement Disorders · doi:10.1002/mds.21197 · Cited by 101 · see citing works
Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease
Boll, M.-C., Sotelo, J., Otero, E., Alcaraz-Zubeldia, M., & Rios, C. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00221-9 · Cited by 92 · see citing works
Self-citationFunctional relevance of ceruloplasmin mutations in Parkinson's Disease
Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Krüger, R., Becker, G., Riess, O., & Berg, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3486fje · Cited by 87 · see citing works
Tsai, C., Wu, R., Huang, Y.-W., Chen, L., Yip, P., & Jeng, J. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0403-9 · Cited by 76 · see citing works
Predictive value of transcranial sonography in the diagnosis of Parkinson's disease
Prestel, J., Schweitzer, K. J., Hofer, A., Gasser, T., & Berg, D. (2006) · Movement Disorders · doi:10.1002/mds.21054 · Cited by 62 · see citing works
Application of Transcranial Sonography in Extrapyramidal Disorders: Updated Recommendations
Berg, D., Behnke, S., & Walter, U. (2006) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-2005-858962 · Cited by 49 · see citing works
Hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain
Tajima, K., Kawanami, T., Nagai, R., Horiuchi, S., & Kato, T. (1999) · Neurology · doi:10.1212/wnl.53.3.619 · Cited by 17 · see citing works
A new method for assay of ferroxidase activity and its application to human and rabbit sera.
Tanabe, S., SHIOIRI, T., Murakami, K., & Imanari, T. (1984) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.32.4029 · Cited by 11 · see citing works
Flagged first, then by citations
1 of the 24 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819 · see citing works
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Ayton, S., Lei, P., Duce, J. A., Wong, B. X. W., Sedjahtera, A., Adlard, P. A., Bush, A. I., & Finkelstein, D. I. (2013) · Annals of Neurology · doi:10.1002/ana.23817 · Cited by 264 · see citing works
The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases
Dušek, P., Roos, P. M., Litwin, T., Schneider, S. A., Flaten, T. P., & Aaseth, J. (2014) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.05.007 · Cited by 253 · see citing works
The transition metals copper and iron in neurodegenerative diseases
Rivera-Mancía, S., Pérez‐Neri, I., Rı́os, C., Tristán-López, L. A., Rivera-Espinosa, L., & Montes, S. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.04.010 · Cited by 243 · see citing works
Self-citationCopper and Copper Proteins in Parkinson’s Disease
Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., & Rios, C. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/147251 · Cited by 203 · see citing works
Self-citationAyton, S., & Lei, P. (2014) · BioMed Research International · doi:10.1155/2014/581256 · Cited by 161 · see citing works
Abnormal Copper Homeostasis: Mechanisms and Roles in Neurodegeneration
Manto, M. U. (2014) · Toxics · doi:10.3390/toxics2020327 · Cited by 118 · see citing works
The effect of abnormal iron metabolism on osteoporosis
Che, J., Yang, J., Zhao, B., Zhang, G., Wang, L., Peng, S., & Shang, P. (2020) · Biological Trace Element Research · doi:10.1007/s12011-019-01867-4 · Cited by 113 · see citing works
Iron Metabolism in Aging and Age-Related Diseases
Tian, Y., Tian, Y., Yuan, Z., Zeng, Y., Wang, S., Fan, X., Yang, D., & Yang, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073612 · Cited by 104 · see citing works
Investigation of serum proteome alterations in human glioblastoma multiforme
Gollapalli, K., Ray, S., Srivastava, R., Renu, D., Singh, P., Dhali, S., Dikshit, J. B., Srikanth, R., Moiyadi, A. V., & Srivastava, S. (2012) · PROTEOMICS · doi:10.1002/pmic.201200002 · Cited by 68 · see citing works
Li, D., He, Y.-C., Liu, J., & Chen, S. (2016) · Scientific Reports · doi:10.1038/srep20863 · Cited by 66 · see citing works
Kurnik‐Łucka, M., Panula, P., Bugajski, A. J., & Gil, K. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9818-6 · Cited by 64 · see citing works
Serum microRNA-133b is associated with low ceruloplasmin levels in Parkinson's disease
Zhao, N., Jin, L., Fei, G., Zheng, Z.-Y., & Zhong, C. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.08.016 · Cited by 48 · see citing works
Shafieesabet, A., Fereshtehnejad, S., Shafieesabet, A., Delbari, A., Baradaran, H. R., Postuma, R. B., & Lökk, J. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.06.006 · Cited by 42 · see citing works
Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synopsis of recent studies
Snædal, J., Kristinsson, J. R., Johannesson, & Tórsdóttir, G. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s34729 · Cited by 41 · see citing works
Sahoo, P. K., Das, S., Mahapatra, K. D., Saha, J. N., Baranski, M., Ødegård, J., & Robinson, N. A. (2013) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2013.02.020 · Cited by 37 · see citing works
Mariani, S., Ventriglia, M., Simonelli, I., Spalletta, G., Bucossi, S., Siotto, M., Assogna, F., Melgari, J.-M., Vernieri, F., & Squitti, R. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00037 · Cited by 35 · see citing works
Wong, B. X. W., Ayton, S., Lam, L. Q., Lei, P., Adlard, P. A., Bush, A. I., & Duce, J. A. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.08.006 · Cited by 31 · see citing works
Kim, J. Y., Kim, S.-K., Kang, D., & Moon, M. H. (2012) · Analytical Chemistry · doi:10.1021/ac300772w · Cited by 30 · see citing works
Role of Iron and Copper in the Pathogenesis of Parkinson’s Disease
Gangania, M. K., Batra, J., Kushwaha, S. S., & Agarwal, R. (2016) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-016-0614-5 · Cited by 29 · see citing works
A low blood copper concentration is a co-morbidity burden factor in Parkinson’s disease development
Ilyechova, E. Y., Miliukhina, I. V., Orlov, I. A., Muruzheva, Z. M., Puchkova, L. V., & Karpenko, M. N. (2017) · Neuroscience Research · doi:10.1016/j.neures.2017.11.011 · Cited by 27 · see citing works
Rivera-Mancía, S., Jiménez‐Osorio, A. S., Medina‐Campos, O. N., Colin-Ramírez, E., Vallejo, M., Alcántara-Gaspar, A., Cartas-Rosado, R., Vargas‐Barrón, J., & Pedraza‐Chaverrí, J. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15122687 · Cited by 22 · see citing works
Metallomics Applied to the Study of Neurodegenerative and Mental Diseases
Sussulini, A., & Hauser‐Davis, R. A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-90143-5_2 · Cited by 21 · see citing works
Jin, L., Wan, W., Wang, L., Wang, C., Xiao, J., Zhang, F., Zhao, J., Wang, J., Zhan, C., & Zhong, C. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.09.034 · Cited by 21 · see citing works
Rubio‐Osornio, M., Orozco‐Ibarra, M., Dı́az-Ruiz, A., Brambila, E., Boll, M., Monroy‐Noyola, A., Guevara, J., Montes, S., & Rı́os, C. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.04.016 · Cited by 17 · see citing works
Self-citationEmerging insights into Lipocalin-2: Unraveling its role in Parkinson's Disease.
Qiu, R.-Q., Cai, Y.-J., Su, Y.-N., Fan, K.-L., Sun, Z.-H., & Zhang, Y. (2024) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2024.116947 · Cited by 13 · see citing works
Serúlópasmín og járn. Tengsl við Alzheimersjúkdóm og Parkinsonsjúkdóm
Jóhannesson, Þ., Kristinsson, J., Þórsdóttir, G., Snædal, J., & Snædal, J. (2012) · Læknablaðið · doi:10.17992/lbl.2012.10.457 · Cited by 11 · see citing works
Zhao, N., Xiao, J., Zheng, Z.-Y., Fei, G., Zhang, F., Jin, L., & Zhong, C. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-014-1512-6 · Cited by 8 · see citing works
Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease
Song, Y. S., Kim, J., Kim, K. J., Yun, J. Y., & Kim, S. E. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001734 · Cited by 7 · see citing works
Bakeberg, M. C., Riley, M., Byrnes, M. L., Jefferson, A., Ghosh, S., Horne, M. K., McGregor, S., Stell, R., Walters, S., Evans, T., et al. (2020) · Parkinson s Disease · doi:10.1155/2020/8296203 · Cited by 5 · see citing works
Oxidative modification of human ceruloplasmin induced by a catechol neurotoxin, salsolinol
Kim, S.-S., Kang, J. Y., & Kang, J. H. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.1.103 · Cited by 5 · see citing works
Metal Transporters in Neurodegeneration
Jiang, H. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00016-6 · Cited by 3 · see citing works
Deepika, D., Kumar, J., Ali, S. A., Namdeo, A. G., & Flora, S. J. S. (2026) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2026.127929 · Cited by 1 · see citing works
Bočková, K., & Rektorová, I. (2021) · Neurologie pro praxi · doi:10.36290/neu.2021.042
- Authors
- Martínez-Hernández, R., Montes, S., Higuera-Calleja, J., Yescas, P., Boll, M.-C., Diaz-Ruiz, A., & Rios, C.
- Affiliations
- Instituto Nacional de Neurología y Neurocirugía (MX)
- Venue
- Neurochemical Research
- Published
- 2011-06-26
- Volume
- 36
- Issue
- 11
- Pages
- 2111-2115
- ISSN
- 0364-3190 (ISSN-L)
- 1573-6903
- OpenAlex
- W2055748558
- Cited by
- 34
- References
- 24
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 1 · 2014: 7 · 2013: 2 · 2012: 5
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neurochemical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- Parkinson's disease, ceruloplasmin, ferroxidase activity, substantia nigra, transcranial ultrasound, iron accumulation, brain iron metabolism, plasma biomarkers
- MeSH terms
- Adult, Aged, Ceruloplasmin, Female, Humans, Iron, Male, Middle Aged, Parkinson Disease, Pilot Projects, Substantia Nigra, Ultrasonography, Doppler, Transcranial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
